MedPath

Tolerance and Effectiveness of Cell Therapy by Autologous Apoptotic Cells in the Treatment of Rheumatoid Arthritis

Phase 1
Not yet recruiting
Conditions
Arthritis, Rheumatoid
Interventions
Biological: Autologous apoptotic cells injection
Registration Number
NCT02903212
Lead Sponsor
Centre Hospitalier Universitaire de Besancon
Brief Summary

The aim of the study is to determine the tolerance of apoptotic autologous cells injection in subjects with active rheumatoid arthritis.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
22
Inclusion Criteria
  • Patients with a diagnosis of Rheumatoid arthritis
  • Therapy failure with at least one biological agent from anti-TNF-alpha (etanercept, infliximab, adalimumab, certolizumab and golimumab; 3 months at optimal dose), anti-IL6 (tocilizumab; 3 months); T-cell costimulatory pathway inhibitor (abatacept; 3 months); anti-CD20 (rituximab; 6 months at optimal dose); Anti IL-1 (anakinra; 3 months)
  • Disease Activity Score (DAS) DAS28 ≥ 3.2
  • Subject has provided written informed consent
Exclusion Criteria
  • Pregnant or lactating women
  • Inflammatory arthritis other than rheumatoid arthritis
  • History of invasive cancer
  • Immunodeficiency (HIV infection, Immunosuppressive therapy)
  • Active bacterial or viral infections, in particular HCV or HBV.
  • Surgery not older than 4 weeks.
  • Unstable comorbidities: uncontrolled diabetes, heart disease, advanced renal or hepatic impairment.
  • Contraindication to an apheresis

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Rheumatoid arthritisAutologous apoptotic cells injectionPatients with rheumatoid arthritis. An injection of autologous apoptotic cells is performed on the D0.
Primary Outcome Measures
NameTimeMethod
Tolerance of apoptotic cells injection12 weeks

Side effects are taken into account to assess tolerance.

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath